Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:32 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
RCVS: The Rational Approach to Diagnosis and Treatment
NCT03150524 · Johns Hopkins University · PHASE4 · withdrawn · last registry update 2019-09-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Failure to recruit patients meeting inclusion criteria.” | – | Registry record, Johns Hopkins University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against NR3C2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-06-30Phase 3 first posted: Central Hospital, Nancy, France, Eplerenone 50mg/day (cross over design) (NCT04450953)
- 2020-06-17Phase 3 first posted: Bayer, Finerenone (BAY94-8862) (NCT04435626)
- 2020-05-27Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Investigational products administration + Placebo administration (NCT04404400)
- 2020-02-05Phase 3 first posted: American University of Beirut Medical Center, Dienogest 2 MG Oral Tablet + Yasmin (NCT04256200)
- 2020-01-27Results posted on the registry: Relypsa, Inc., Patiromer + Placebo (NCT03071263)
- 2019-06-11Phase 3 first posted: Children's Mercy Hospital Kansas City, Metformin and Spironolactone (NCT03981861)
- 2019-04-23Phase 3 first posted: University of Edinburgh, Magnesium Sulfate + Nimodipine (NCT03925025)
- 2019-03-25Phase 3 first posted: Vifor Pharma, Inc., Patiromer + Placebos (NCT03888066)
- 2018-12-12Phase 3 first posted: CMC Ambroise Paré, Hydrocortisone + Flucortac (NCT03773822)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision